Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Gliatech (GLIA) -- Ignore unavailable to you. Want to Upgrade?

To: RWReeves who wrote (1490)	3/13/2000 12:34:00 PM
From: biowa	Read Replies (1) \| Respond to of 2001

RWR (and J. de C.) Probably someone on the AVAN thread knows the whole story. It would seem that someone is you. In terms of the relative merits of the GLIA and AVAN approaches, I have always been a little leery of the TP10 approach which claims to shut down both pathways fairly effectively. As the resident SI skeptic (now that the momo has cooled for a moment, maybe there's a point to resuming that role), one of my guiding skepticisms has always been that "nature didn't make it that way for nothing." Thus, I find immune suppression generally disconcerting; and the broader the suppression, the more disconcerting. GLIA properdin approach might be better (as J. de C. noted), or it might not be powerful enough in some acute states. biowa